NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related venous thrombosis.
Research article published in Journal of thrombosis and haemostasis : JTH (2022)
Abstract
BACKGROUND: In critically ill (preterm) neonates, catheter-related venous thromboembolism (CVTE) can be a life-threatening complication. Evidence on optimal management in the literature is lacking. In the Netherlands, a consensus-based national management guideline was developed to create uniform CVTE management. OBJECTIVES: To evaluate the efficacy and safety of the national guideline. METHODS: This prospective, multicenter, observational study included all infants aged ≤6 months with CVTE in the Netherlands between 2014 and 2019. CVTE was divided into thrombosis in veins and that in the right atrium, with their own treatment algorithms. The primary outcomes were recurrent venous thrombotic events (VTEs) and/or death due to CVTE as well as major bleeding. RESULTS: Overall, 115 neonates were included (62% male; 79% preterm). The estimated incidence of CVTE was 4.0 per 1000 neonatal intensive care unit admissions. Recurrent thrombosis occurred in 2 (1.7%) infants and death due to CVTE in 1 (0.9%) infant. Major bleeding developed in 9 (7.8%) infants: 2 of 7 (29%) on recombinant tissue plasminogen activator, which was given for high-risk right-atrium thrombosis, and 7 of 63 (11%) on low-molecular-weight heparin (LMWH). Five of the 7 bleedings because of LMWH were complications of subcutaneous catheter use for LMWH administration. CONCLUSION: The management of neonatal CVTE according to the Dutch CVTE management guideline led to a low incidence of recurrent VTEs and death due to VTEs. Major bleeding occurred in 7.8% of the infants. Specific guideline adjustments may improve efficacy and, especially, safety of CVTE management in neonates.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
In critically ill (preterm) neonates, catheter-related venous thromboembolism (CVTE) can be a life-threatening complication. Evidence on optimal management in the literature is lacking.
Warum dies für die Hirudotherapie relevant ist
Diese prospektive, multizentrische Beobachtungsstudie evaluierte eine nationale Leitlinie zum Management katheterassoziierter venöser Thrombosen bei Neugeborenen und fand eine niedrige Inzidenz rezidivierender Thrombosen und Todesfälle, obwohl schwere Blutungen bei 7,8 % der Säuglinge auftraten, primär assoziiert mit der Gabe von niedermolekularem Heparin. Die Studie untersucht die Sicherheit und Wirksamkeit systemischer antikoagulatorischer und fibrinolytischer Interventionen in einer hochvulnerablen Population. Während Komponenten des Blutegel-Sekretoms antikoagulatorische Eigenschaften besitzen, weist der Fokus dieser Studie auf systemischer, neonataler Zentralvenenkatheter-assoziierter Thrombose praktisch keine klinische Überschneidung mit externer Hirudotherapie auf. Daher besitzt die Studie keine direkte Relevanz für die American Society of Hirudotherapy.
Zitation
NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related venous thrombosis.
van Ommen et al. · Journal of thrombosis and haemostasis : JTH, 2022
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026